CMAs and CQAs of Injectable Products

Concepts

• CMAs (Critical Material Attributes): Properties of API that influence drug product quality.
• CQAs (Critical Quality Attributes): Properties of the final product that must remain within limits to ensure safety, efficacy, and quality.

Link: CMAs of the API directly affect CQAs of the injectable product.

Key CMAs of API for Injectables

• Particle Size Distribution (PSD): Affects dissolution, syringeability, and bioavailability. Oversized → embolism; too fine → dose dumping.
• Polymorphic Form / Crystallinity: Determines solubility and stability; shifts can cause precipitation or potency variation.
• Moisture Content / Hygroscopicity: Promotes degradation, reduces stability, and compromises sterility.
• Purity & Residual Solvents: Must comply with ICH limits; uncontrolled impurities cause toxicity.
• Endotoxin Content: Even trace levels are unacceptable; causes pyrogenic reactions.
• pKa & Solubility Profile: Guides formulation choice (solution vs suspension); poor solubility risks precipitation.
• Bulk Density / Flowability: Impacts sterile processing and vial filling consistency.

Key CQAs of Injectable Products

• Assay / Potency: Ensures correct therapeutic dose.
• Sterility & Endotoxins: Mandatory for patient safety.
• Impurities / Degradation Products: Must be within ICH limits.
• Particulate Matter: Controlled per USP <788>; prevents embolism.
• pH & Osmolarity: Must match physiological conditions.
• Syringeability / Injectability: Ensures smooth administration.
• Release Profile: Critical for bioavailability and therapeutic effect.

CMA → CQA Link

• PSD (CMA) → Dissolution & Syringeability (CQA) → Impacts bioavailability.
• Polymorph (CMA) → Stability & Assay (CQA) → Impacts consistency.
• Endotoxins (CMA) → Endotoxin CQA → Impacts patient safety.
• Residual solvents (CMA) → Impurity profile (CQA) → Impacts toxicity.

Example – Corticosteroid Depot Injection

• Particle size: Controls depot effect and plasma profile.
• Polymorph stability: Prevents precipitation and variability.
• Residual solvents: Must be within ICH limits to avoid toxicity.
• Endotoxin load: Directly affects patient safety.

Takeaway

• CMAs = inputs, CQAs = outputs.
• For injectables, the link is critical due to direct systemic exposure.
• A QbD and risk-based approach ensures consistent quality.

Read also:

• Quality by Design (QbD) in Topical Formulations
• Drug Excipient Compatibility Study During QbD
• Relationship Between QTPP and CQA

Resource Person: Moinuddin Syed. Ph.D, PMP®